Human Genome Epidemiology Literature Finder
|
Records 1 - 10 (of 10 Records) |
| Query Trace: Lymphoma and CYP3A4[original query] |
|---|
| Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenetics and genomics 2007 Jun 17 (6): 431-45. Nakajima Miki, Komagata Sayaka, Fujiki Yuto, Kanada Yoshihiro, Ebi Hiromichi, Itoh Kuniaki, Mukai Hirofumi, Yokoi Tsuyoshi, Minami Hirono |
| Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis. Blood 2009 Apr 113 (14): 3307-13. Ribrag Vincent, Koscielny Serge, Casasnovas Olivier, Cazeneuve Cecile, Brice Pauline, Morschhauser Franck, Gabarre Jean, Stamatoullas Aspasia, Lenoir Gilbert, Salles Gilles, |
| Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis 2008 Oct 29 (10): 1955-62. Figueroa Jonine D, Malats Núria, García-Closas Montserrat, Real Francisco X, Silverman Debra, Kogevinas Manolis, Chanock Stephen, Welch Robert, Dosemeci Mustafa, Lan Qing, Tardón Adonina, Serra Consol, Carrato Alfredo, García-Closas Reina, Castaño-Vinyals Gemma, Rothman Nathani |
| Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Feb 15 (4): 1496-503. Woo Sukyung, Gardner Erin R, Chen Xiaohong, Ockers Sandra B, Baum Caitlin E, Sissung Tristan M, Price Douglas K, Frye Robin, Piekarz Richard L, Bates Susan E, Figg William |
| Pharmacogenetic analysis in the treatment of Hodgkin lymphoma. Leukemia & lymphoma 2013 Aug 54 (8): 1706-12. Altés Albert, Paré Laia, Esquirol Albert, Xicoy Blanca, Rámila Elena, Vicente Laura, López Rosario, Orriols Jaume, Vall-llovera Ferran, Sánchez-González Blanca, del Río Elisabeth, Sureda Anna, Páez David, Baiget Montserr |
| Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer. Cancer chemotherapy and pharmacology 2017 Jul . Mbatchi Litaty C, Gassiot Matthieu, Pourquier Philippe, Goberna Alejando, Mahammedi Hakim, Mourey Loic, Joly Florence, Lumbroso Serge, Evrard Alexandre, Houede Nadi |
| Pharmacogenetics-Based Preliminary Algorithm to Predict the Incidence of Infection in Patients Receiving Cytotoxic Chemotherapy for Hematological Malignancies: A Discovery Cohort. Frontiers in pharmacology 2021 3 12 602676. Martinez Matias F, Alveal Enzo, Soto Tomas G, Bustamante Eva I, Ávila Fernanda, Bangdiwala Shrikant I, Flores Ivonne, Monterrosa Claudia, Morales Ricardo, Varela Nelson M, Fohner Alison E, Quiñones Luis |
| Prediction of trough concentration and ALK occupancy in plasma and cerebrospinal fluid using physiologically based pharmacokinetic modeling of crizotinib, alectinib, and lorlatinib. Frontiers in pharmacology 2023 12 14 1234262. Bole Li, Shan Liu, Honglei Feng, Chunshuang Du, Liman Wei, Jie Zhang, Guangwei Jia, Chunnuan |
| Case report: dose-dependent interaction between dexamethasone and voriconazole in severely ill patients with non-Hodgkin's lymphoma being treated for invasive pulmonary aspergillosis. Frontiers in pharmacology 2024 7 15 1403966. Jingjing Huang, Yang Chen, Ming Zhong, Ruoming T |
| Sex and common germline variants impact the toxicity profile and pharmacokinetics of alectinib: a nation-wide cohort study in patients with ALK-positive non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2024 12 . Niels Heersche, Daan A C Lanser, M Benthe Muntinghe-Wagenaar, Ma Ida Mohmaed Ali, Ezgi B Ulas, Tessa M A Trooster, Evert de Jonge, Esther Oomen-de Hoop, Marthe S Paats, Idris Bahce, Sander Croes, Lizza E L Hendriks, Anthonie J van der Wekken, Anne-Marie C Dingemans, Alwin D R Huitema, Ron H N van Schaik, Ron H J Mathijssen, G D Marijn Veerm |
- Page last reviewed:Feb 1, 2024
- Content source: